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Abstract
Ceruloplasmin (Cp) is an essential ferroxidase that plays important roles in cellular iron trafficking. Previous findings suggest
that the proper regulation and subcellular localization of iron are very important in brain cell function and viability. Brain
iron dyshomeostasis is observed during normal aging, as well as in several neurodegenerative disorders such as Alzheimer’s,
Parkinson’s and Huntington’s diseases, coincident with areas more susceptible to insults. Because of their high metabolic
demand and electrical excitability, neurons are particularly vulnerable to ischemic injury and death. We therefore set out to
look for abnormalities in the brain of young adult mice that lack Cp. We found that iron levels in the striatum and cerebral
cortex of these young animals are significantly lower than wild-type (WT) controls. Also mRNA levels of the neurotrophin
brain derived neurotrophic factor (BDNF), known for its role in maintenance of cell viability, were decreased in these
brain areas. Chelator-mediated depletion of iron in cultured neural cells resulted in reduced BDNF expression by a
posttranscriptional mechanism, suggesting a causal link between low brain iron levels and reduced BDNF expression. When
the mice were subjected to middle cerebral artery occlusion, a model of focal ischemic stroke, we found increased brain
damage in Cp-deficient mice compared to WT controls. Our data indicate that lack of Cp increases neuronal susceptibility to
ischemic injury by a mechanism that may involve reduced levels of iron and BDNF.
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Introduction
Iron is an essential nutrient that plays an important role in
myelination, energy production and cell cycling; also it serves as a
cofactor for enzymes involved in neurotransmitter production and
metabolism, DNA synthesis and purine catabolism. [1,2]. All of
these actions are mediated by the transition metal property of
iron that allows it to act as an electron donor or acceptor.
Unfortunately, the same property that makes iron so useful can
also lead to cell damage through formation of hydroxyl radicals
when ferrous iron interacts with hydrogen peroxide in the Haber-
Weiss-Fenton reaction [3]. Regulation of iron homeostasis is thus
extremely important because of its dual nature [4]. One of the
proteins involved in controlling iron trafficking is the essential
ferroxidase ceruloplasmin (Cp), which acts to convert the reactive
ferrous (Fe
2+) form of iron to the much less toxic ferric (Fe
3+) form ,
therefore facilitating transferrin-mediated transport [5].
Cp is an abundant plasma protein also found in the brain in
both a secreted form and a glycosylphosphatidylinositol (GPI)-
linked isoform on the plasma membrane of astrocytes [6]. Patients
affected by aceruloplasminemia lack Cp and develop progressive
iron accumulation in organs such as the liver, pancreas and
retina; as these patients age, iron also accumulates in the brain,
particularly in the basal ganglia and substantia nigra, which results
in neuronal degeneration and neurological symptoms [7].
Similarly Cp knockout (CpKO) mice develop age-dependent iron
deposits in the cerebellum, brain stem and cervical spinal cord
leading to neurological deficits [8]. Experiments have demon-
strated that the absence of Cp in both humans [9,10] and mice
[11,12] render neurons more susceptible to insults, suggesting a
role for Cp in neuronal survival.
Increases in free iron levels have been observed in the brain
during global [13] and focal ischemia [14]. The role played by
iron in ischemic brain injury is complex. The ability of iron
chelators or antioxidants treatments to reduce ischemic brain
injury has generally been linked to the capacity of Fe
2+ to induce
lipid peroxidation and oxidative damage [15–17]. However,
additional mechanisms are likely involved. Iron is critical for the
function of numerous enzymes involved in neuronal metabolism,
plasticity and survival. For example, mitochondria rely upon heme
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clusters containing complexes (I–III), in the electron transport
chain and enzymes of the citric acid cycle [18]. Because
mitochondrial function is compromised in stroke, reduced iron
levels may exacerbate ischemia-related cellular energy deficits.
Also, enzymes involved in the production and metabolism of
monoamine neurotransmitters also require iron [19], and two of
these neurotransmitters (serotonin and norepinephrine) have been
reported to modify brain damage in animal models of stroke
[20,21]
In response to cerebral ischemia the production of several
neurotrophic factors, including fibroblast growth factor 2, insulin-
like growth factor 1 and brain-derived neurotrophic factor (BDNF)
is increased [22–24]. Activation of receptors for each of the latter
trophic factors can protect neurons against ischemic brain injury
in experimental cell culture and animal models [25–28]. The
expression of BDNF by neurons is sensitive to iron levels as
demonstrated by studies showing that dietary iron deficiency
reduce BDNF expression without affecting expression of the
BDNF receptor TrkB [29]. Also in patients with neurodegener-
ative diseases, such as Parkinson’s, Huntington’s and Alzheimer’s,
brain iron dysregulation is found together with decreases in BDNF
[30]. BDNF administration has been has also been shown to
promote cell viability after insults [31] and the increased BDNF
production after exercise and caloric restriction is believed to play
a major role in the neuroprotective effects of these treatments [32].
In the present study we demonstrate that iron levels are reduced
in the cerebral cortex and striatum of young adult CpKO mice,
and that the reduction in iron is associated with reduced BDNF
expression. CpKO mice exhibit increased brain damage in a
model of focal ischemic stroke, suggesting an important role for
cellular iron homeostasis in neuronal resistance to ischemic injury.
Results
Ceruloplasmin deficiency results in reduced
concentrations of iron in the cerebral cortex and striatum
Cp plays a key role in iron regulation. To determine if the
absence of Cp altered brain iron levels, biopsy punches were taken
from the cerebral cortex and striatum of young 3 month-old WT
and CpKO mice. These punches were analyzed for iron levels
using atomic absorption spectroscopy. Levels of iron were
normalized to the sample weight. The CpKO mice had a
significantly lower concentration of iron in both the cortex and
striatum compared to WT mice (Fig. 1). This result is very
interesting considering that 3 month-old CpKO mice already
display a hepatic iron overload phenotype [33]. The discrepancy
between brain and peripheral iron levels is likely due to the tight
control exerted by the brain blood barrier in regulating cerebral
iron influx/efflux [34].
BDNF expression is reduced in the cerebral cortex and
striatum of ceruloplasmin-deficient mice
There are several different BDNF transcripts produced in the
mouse. Their expression is stimulated through various mecha-
nisms, but all result in the same final BDNF protein [35]. Using
real-time PCR we measured levels of 4 different transcripts of
BDNF in the cerebral cortex and striatum of young 3 month old
CpKO mice. We found that levels of BDNF transcripts I, II and
IV were significantly reduced in the cortex of CpKO mice
compared to 3 month old WT mice (Fig. 2A). Levels of BDNF
transcripts I, II, III and IV were significantly reduced in the
striatum of the CpKO mice compared to WT controls (Fig. 2B).
Measurements of the transcripts of both short and long forms of
the BDNF receptor TrkB did not show differences between WT
and Cp KO animals in either the cortex or striatum (data not
shown). Western blots also demonstrated a significant decrease in
BDNF protein levels in both the striatum and cortex in the CpKO
compared to WT animals (Fig. 2C).
To better explore the connection between iron and BDNF levels
we employed a cell culture model (human SH-SY5Y neuroblas-
toma cells). The cells were treated for 24 hours with the iron
chelator deferoxamine. Similar to what was observed in vivo in
CpKO mice, decreasing iron availability resulted in a significant
decrease of BDNF transcript levels (Fig. 3A) without effecting cell
viability (Fig. 3B). When SH-SY5Y cells were transfected with
reporters for BDNF promoters I–IV and then subjected to iron
chelation, no differences in reporter activity were observed
amongst control or deferoxamine treated cells (Fig. 3C). Taken
together, our data suggest that iron regulates BDNF at a post-
transcriptional level, possibly by accelerating the decay of BDNF
mRNAs.
CpKO mice sustain greater brain damage after MCAO
Three month old WT and CpKO mice were subjected to
45 minutes of MCAO followed by 72 hours of reperfusion. Infarct
volume was measured by image analysis of TTC-stained brain
sections (Fig. 4A). We found that cell death in the striatum was
extensive and there was no significant difference in the amount of
damage between CpKO and WT mice. However, the extent of
cell death in the cerebral cortex was significantly greater in the
CpKO mice compared to WT mice (Fig. 4B). These results may
be explained by the fact that the striatum has less collateral blood
flow than cortex [36]; consequently 45 minutes of ischemia
produces near maximal damage in the striatum but submaximal
damage in the cortex. Thus, in our experimental model the ‘‘core’’
striatal damage is maximal and not impacted by CP deficiency.
On the other hand, in the cortical ‘‘penumbra’’ region the reduced
levels of total iron and BDNF in the CpKO mouse render the
Figure 1. CpKO mice have decreased concentrations of iron in
the cerebral cortex and striatum. Atomic absorption measures of
cortical and striatal biopsy punches show significant decreases in iron
concentrations in CpKO compared to wild type mice in both the
cerebral cortex ( n=18; *p,0.02) and the striatum (n=7; *p,0.03).
doi:10.1371/journal.pone.0025077.g001
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exacerbating the stroke outcome.
Because Fe
2+ may promote the generation of reactive oxygen
species (ROS), which can lead to lipid peroxidation and
peroxynitrite production [37], we measured markers of oxidative
stress that have previously been associated with ischemic brain
injury. After 24 hours reperfusion, the lipid peroxidation product 4-
hydroxynonenal and nitrotyrosines were elevated in both the
ipsilateral and contralateral cerebral hemisphere in WT mice
subjected to stroke compared to sham-operated control mice
(Fig. 5A, B). Similar results were obtained in CpKO mice with no
significant differences in levels of 4-hydroxynonenal or nitrotyrosine
between WT and CpKO mice, although trends towards reduced
levels of these markers were observed in the ipsilateral cortex of
CpKO compared to WT mice (Fig. 5A, B). In addition, we found
that levels of GFAP, a marker of reactive astrocytes, were increased
in both hemispheres in response to stroke with no significant
differences between WT and CpKO mice (Fig. 5C). Levels of
proinflammatory cytokines (IL-1Beta, TNF-alpha and IL-6)
measured in brain tissue samples collected 3 hours after reperfusion
were also not significantly different between WT and CpKO mice
in either hemisphere (Fig. 5D, E, F). These data further support the
hypothesis that the decreases in iron and BDNF in the CpKO
mouse contributes to the larger infarct volume, rather than
differences in levels of oxidative stress and inflammation.
Discussion
Ceruloplasmin is a key regulator in iron metabolism and its loss
has been shown to cause age-dependent iron dysregulation in
humans and animal models [6,33,38]. We found that total iron
levels in the cerebral cortex and striatum of young CpKO mice
were significantly lower than WT mice. This iron deficit was
concurrent with decreased levels of BDNF mRNA and protein.
The extent of brain damage caused by MCAO reperfusion was
significantly greater in the CpKO mice compared to WT mice, as
a result of the expansion of the damage in the ischemic penumbra
region of the cerebral cortex. These findings suggest that lack of
Cp can cause a change in brain iron and BDNF levels, which
normally play important roles in protecting neurons against
ischemic brain injury.
Previous studies of other lines of CpKO mice have shown that
iron levels increase in the brain stem, cerebellum and spinal cord
as they age [8,38]. However, levels of iron in striatum and cerebral
cortex, from young CpKO mice have not been reported in the
latter studies. The larger infarct volume we observed in the CpKO
mice after MCAO, suggests that lack of Cp may affect the
vulnerability of cortical and striatal neurons. While the present
study is the first to examine the effects of ceruloplasmin deficiency
on the vulnerability of the brain to ischemic stroke, Rathore et al.
[12] demonstrated that young CpKO mice show increased
secondary damage coupled with oxidative damage and a decrease
in functional recovery after spinal cord injury compared to WT
animals. Previous evidence has also shown enhanced levels of
oxidative stress markers in the brain of patients with aceruloplas-
minemia [39,40], as well as in the hippocampus of CpKO mouse
compared to WT following 4 weeks of rotenone treatment [11].
However, in our experimental model we found no evidence of
increased lipid peroxidation or astrocyte reactivity the in cortex or
Figure 2. The expression of BDNF is reduced in the cerebral cortex and striatum of ceruloplasmin-deficient mice. A. RT-PCR measures
of the 4 BDNF transcripts show a decrease in BDNF transcripts 1, 2 and 4 in the cortex of the CpKO mouse (*p,0.04, n=5). B. RT-PCR measures of the
4 BDNF transcripts show a decrease in BDNF transcripts 1, 2, 3 and 4 in the striatum of the CpKO mouse (*p,0.05, n=5). C. Examples of immunoblots
of BDNF protein levels in the cortex and striatum (top panel) and densitometry results showing significant decreases BDNF protein levels (normalized
to actin level) using Image J software. (*p,0.03; n=4 WT and 3 CpKO mice).
doi:10.1371/journal.pone.0025077.g002
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24 hours after the insult. We also did not observe increased
proinflammatory cytokine levels 3 hours after the insult. These
findings suggest that Cp deficiency and reduced iron levels do not
alter levels of membrane-associated oxidative stress or generation
of proinflammatory cytokines by glial cells. However, we cannot
exclude the possibility that Cp and/or iron levels modify oxidative
stress and inflammatory processes during the later post-stroke
period.
The majority of the literature on cerebral ischemia and iron
indicate that increased levels of iron contributing to the
exacerbation of infarct volume or functional recovery. Elevated
iron levels may contribute to ischemic brain injury by promoting
the production of hydroxyl radicals and consequent lipid
peroxidation [41]. Human studies have also shown that increased
iron stores are associated with a worse outcome after stroke [42].
Studies involving iron chelators have demonstrated reduced
infarct size with both pre and post [43–45]. The mechanisms in
which chelators promote protection though, may not be due just to
their reduction of free iron but to other factors such as HIF
activation [46,47] or reduction of brain edema [41]. Toxicity from
iron during ischemia likely arises from liberation of iron from high-
molecular weight storage proteins [13]. We found decreased
concentrations of iron in the cortex and striatum of CpKO mice in
conjunction with increased infarct volumes. This counterintuitive
result may be due to the particular importance of iron in the brain.
While high levels of iron may be toxic, it is also true that
abnormally low levels of iron will make cells more sensitive to
insults by impairing normal brain functions which rely on
adequate iron supply, such as ATP production, regulation of
cellular energy, myelination and neurotransmitter production
[41]. Interestingly, others have shown that increases in infarct
volume after MCAO in rats on high iron diets were not associated
with alterations in brain iron levels [48]. Consistently, aggressive
iron chelator treatment in rats was not able to reduce infarct
volume following ischemia [49]. This supports our hypothesis that
reduced brain iron may increase neuronal vulnerability.
Previous studies have demonstrated that BDNF can protect
neurons against cerebral ischemic damage in animal models [50–52]
and against more specific insults relevant to ischemic stroke including
glucose deprivation, excitotoxicity and oxidative stressors [53–55].
BDNF is known to promote the plasticity and survival of neurons,
playing key roles in adaptive responses of the brain to environmental
challenges[56].Studiesinratshaveshownthatcerebral ischemia can
differently affect BDNF levels in the core, where a decrease occurs,
and penumbra areas where an increase occurs [57], supporting a role
for protection by BDNF. Indeed studies in both mice and rats have
demonstrated that administration of exogenous BDNF can promote
Figure 3. Iron chelation decreases BDNF expression in human neuroblastoma cells. A. SH-SY5Y cells were treated with either vehicle
or 100 mM deferoxamine (DFO) for 24 hours. RT-PCR measures of BDNF transcripts show a decrease in total BDNF transcripts (tBDNF, variants 1–14,
16–18 (*p,0.01, n=4–5). B. Iron chelation did not cause changes in cell survival as assessed by trypan blue exclusion 24 hours post-treatment (n=5).
C. SH-SY5Y cells were transfected with luciferase reporters for the promoter regions of BDNF I–IV and were then treated with 100 mM deferoxamine
for 24 hours. No significant differences were observed between control and treated cells (n=3–4).
doi:10.1371/journal.pone.0025077.g003
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ischemia [58,59,52]. Similarly, studies using interventions known to
up regulate basal BDNF levels, such as dietary restriction, enriched
environment or exercise, have shown decreased infarct volumes
following MCAO [60–63]. Conversely decreasing BDNF levels or
attenuating its effects following cerebral ischemia diminishes recovery
of function [64,65]. BDNF has been shown to exert anti-apoptotic
and neuroplastic properties, as well as to enhance neuro- and angio-
genesis. There is also evidence that BDNF levels can modulate
cortical excitability with lower levels of BDNF enhancing excitability
[66]. More specifically, lack of BDNF transcript IV has been show to
cause impairment in cortical inhibitory signaling [67]. Our finding of
reduced BDNF transcript levels, including transcript IV, in the
CpKO mice suggests a mechanism whereby perturbed cellular iron
metabolism in brain cells results in reduced BDNF levels in neurons
which renders them vulnerable to ischemic injury. Indeed, we found
that chelation of cellular iron in results in a reduction in BDNF
mRNA levels in cultured neural cells. The lack of changes in BDNF
promoter-driven luciferase activity following deferoxamine, suggests
that the reduction in BDNF mRNA is likely the result of decreased
mRNA stability. Notably, iron has been shown to play a role in the
regulation of transcript stability in various experimental models by
modifying the ability of iron-responsive proteins to bind to specific
stabilizing/destabilizing sequences at the 39 and/or 59 of mRNA
untranslated regions [68,69].
Because aceruloplasminemia’s most striking symptoms manifest
late in life, studies looking at iron brain levels in pre-symptomatic
young patients, or in young rodent models of aceruloplasminemia
may provide novel insight into the roles of cellular iron metabolism
in developmental neuroplasticity and disease vulnerability. Our
data clearly show that the lack of Cp leads to an early-on reduction
in total brain iron and BDNF levels, resulting in increased
vulnerability of neurons to ischemic injury .
Materials and Methods
Mice
Ceruloplasmin knock-out (CpKO) mice were generated as
described previously [33]. Wild type (WT) and CpKO strains were
maintained according to National Institutes of Health and Johns
Hopkins University guidelines. All procedures on animals were
approved by the Animal Care and Use Committee of the National
Institute on Aging Intramural Research Program. In addition,
procedures for producing middle cerebral artery occlusion
(MCAO) were approved by the Animal Care and Use Committee
of Johns Hopkins University.
Brain iron analysis
Brain regions (n=16/group) were wet digested in 0.2%
ultra-pure nitric acid using standard procedures and analyzed
for iron concentration by atomic absorption spectrometry (Perkin
Elmer Analyst 600, Perkin Elmer, Norwalk, CT) [70]. Standards
were prepared by diluting a Perkin Elmer iron standard
(PE#N9300126) in 0.2% ultra-pure nitric acid, and blanks were
prepared with digesting and diluting reagents to control for
possible contamination. All standard curves exceeded r.0.99.
RNA extraction and real-time PCR
RNA was isolated using Trizol (Invitrogen) and purified with an
RNA Micro Kit (Qiagen, Valencia, CA). Following treatment with
DNAse I, RNA was quantified and equal amounts were retro-
transcribed using the SuperScript First Strand Synthesis System
(Invitrogen Life Technologies). Real-time PCR analysis was
performed with a PTC 200 Pelthier Thermo Cycler and Chromo
4 Fluorescent Detector (BioRad, Hercules, CA), and SybrH Green
PCR Master Mix according to the manufacturer’s instructions
(Applied Biosystems, Foster City, CA). Each reaction included 3 ml
of diluted (1:4) cDNA and was performed in triplicate. PCR was
performed under the following conditions: 10 min at 95uC,
followed by 40 cycles of 30 s at 95uC, 30 s at 60uC and 1 min
at 72uC. The comparative Ct method was used to determine the
normalized changes of the target gene relative to a calibrator
reference. The primers used in this study were as follows:
Figure 4. CpKO mice have increased cerebral infarct volume
after focal ischemic stroke. A. Representative images of TTC-stained
brain sections in mice subjected to 45 min MCAO with a 72 hours
post-stroke survival. B. Calculation of percent infarct volume show a
significant increase in the cortex and hemisphere of the CpKO mice
compared to WT mice. (*p,0.002; n=8 WT and 6 KO mice).
doi:10.1371/journal.pone.0025077.g004
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AGG GTT -39 and 59- ACC TGG TGG AAC ATT GTG GCT
TTG -39; mBDNF2 (NM_001048139), 59- TGA AGT TGG CTT
CCT AGC GGT GTA -39 and 59- TGG TGG AAC TTC TTT
GCG GCT TAC -39; mBDNF3 (NM_001048141) 59- CCA GAG
CAG CTG CCT TGA TGT TTA -39 and 59- CCG CCT TCA
TGC AAC CGA AGT AT -39; mBDNF4 (NM_001048142), 59-
TGA CAA CAA TGT GAC TCC ACT GCC -39 and 59- ATG
GTC ATC ACT CTT CTC ACC TGG -39; tBDNF (X91251.1 )
59- AGA AGA GCT GTT GGA TGA GGA CCA-39 and 59-
AGG CTC CAA AGG CAC TTG ACT ACT-39; HPRT
(NM_013556), 59- CCT GCT GGA TTA CAT TAA AGC
ACT G-39 and 59- CCT GAA GTA CTC ATT ATA GTC AAG
G-39.
Cell transfection and reporter assay
Human neuroblastoma SH-SY5Y cells were transfected with 1 mg
of BDNF(I–IV)-driven luciferase reporter and 0.2 mgo fp R L - T K
vector (Promega, Madison, WI) expressing renilla luciferase using
Fugene6(Roche,Nutley,NJ).Luciferaseactivitywasquantifiedusing
a Dual Luciferase Reporter System 24 hours post transfection.
Immunoblot Analysis
Proteins were extracted from cortex or striatum in WT (n=4) or
CpKO (n=3) mouse brain tissue; 60 mg of protein was separated
by Novex Bis-Tris PAGE (4–12%) and then transferred to a PVDF
membrane. The membrane was blocked in 5% non-fat milk for
1 hour at room temperature, followed by an overnight incubation
at 4uC with primary antibodies against: actin (Sigma); BDNF
(Santa Cruz); 4-hydroxynonenal [71] nitrotyrosine (Millipore);
GFAP (Sigma). Membranes were then washed and incubated with
secondary antibodies for 1 hour at room temperature. Protein
bands were visualized using a chemiluminescence detection kit
(Amersham Biosciences, Piscataway, NJ, USA). Densitometry
measurements were made using Image J software and protein
levels were normalized to actin.
Mouse model of MCAO
Mice were housed in a room at a temperature of 2261uC and
12 hours dark and light cycle. Standard chow pellets and water
was allowed ad libitum. CpKO and wild type mice (22–28 g) were
anesthetized with isoflurane (induction with 2,5% and main-
tained on 1%). The concentration of inspired oxygen was adjusted
Figure 5. CpKO mice do not exhibit increased levels of oxidative stress, glial reactivity or cytokine levels in the cerebral cortex. A–C.
Densitometry measures of 4-hydroxynonenal (4HNE) (A), Nitrotyrosine (B) and GFAP (C) in the cortex of sham operated animals and MCAO operated
animals from the ischemic or contralateral side (24 hours after reperfusion). No differences were seen between genotypes (n=4). Protein levels were
normalized to actin. D–F. Bio-Plex measurements of the cytokines IL-1b, TNF-a and IL-6 in pg/mL in the cortex of CpKO and WT animals 3 hours after
reperfusion (n=7 per group). No significant differences were seen between the two groups.
doi:10.1371/journal.pone.0025077.g005
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a heating pad during the surgery. Mice underwent 45 min MCAO
with 72 hours of reperfusion by the standard trans-luminal
method, which has been described in previous reports [72].
Briefly, the right common carotid artery (CCA) was exposed
through a 15 mm medial line incision of the neck beneath the jaw.
The external carotid artery (ECA) was carefully separated from
the adjacent vagus nerve and tissues and isolated for a length of 3–
5 mm away from the bifurcation of CCA, and the distal end was
coagulated and cut off. The proximal end of CCA was temporarily
ligated using a 6-0 suture. Then a 7-0 nylon monofilament coated
with silicone was inserted from the distal end of the isolated ECA
and was gently introduced into the internal carotid artery and
advanced approximately 6–8 mm past the carotid bifurcation to
the origin of the middle cerebral artery (MCA). Successful MCAO
was confirmed by decreased cerebral blood flow in the territory of
the MCA measured by laser-Doppler flowmetry (LDF; Moor
Instruments Ltd.; Model MBF3D). The onset of ischemia was
designated at the time when the blood flow had decreased to below
30% of the baseline blood flow. The suture remained in situ for
45 min, and then reperfusion of the MCA was initiated by
withdrawal of the filament and release of the CCA ligature. Mice
were euthanized 72 hours after the stroke and infarct volumes
were quantified using standard volumetric analysis with correction
for swelling. The brain was chilled and the cerebrum was sliced
into 5 pieces of 1 mm coronal sections. The slices were then
incubated in 1% triphenyltetrazolium choloride (TTC) in
phosphate buffer, and stained at 37uC for 10–15 min. Both
anterior and posterior views of 5 coronal sections were captured
with a digital camera and the infarct areas were traced using the
SigmaScan Pro, Image analysis, Version 5.0 (SPSS Inc.). Infarct
volume was analyzed on 8 WT and 6 CpKO brains.
Levels of Cytokines
Murine cytokine levels from CpKO (n=7) and WT (n=7) mice
were analyzed using Bio-Plex Mouse Cytokine Singleplex kits
according to the manufacturer’s instructions (Biorad Laboratories,
Hercules, CA). The results are expressed as pg/mL and all assays
were run in duplicate.
Statistical Analysis
Statistical significance was determined using the Student’s t-test
with a p-value less than 0.05 proving statistical significance. Error
bars represent the standard error.
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